Clinical Nephrology – Epidemiology – Clinical Trials
Kidney International (2005) 67, 278–284; doi:10.1111/j.1523-1755.2005.00079.x
B-type natriuretic peptide for acute dyspnea in patients with kidney disease: Insights from a randomized comparison
CHRISTIAN MUELLER, KIRSTEN LAULE-KILIAN, ANDRÉ SCHOLER, CHARLY NUSBAUMER, THOMAS ZELLER, DANIEL STAUB and ANDRÉ P PERRUCHOUD
University of Basel, University Hospital, Department of Internal Medicine, Medical Division A, Basel, Switzerland; and the Department of Laboratory Medicine, Basel,. Switzerland
Correspondence: Professor Dr Christian Mueller, Medizinische Klinik A, Universitätsklinik, Petersgraben 4, CH – 4031 – Basel, Switzerland. E-mail:chmueller@uhbs.ch
Received 30 March 2004; Revised 29 May 2004; Re-revised 15 June 2004; Re-revised 20 July 2004; Accepted 4 August 2004.
Abstract
B-type natriuretic peptide for acute dyspnea in patients with kidney disease: Insights from a randomized comparison.
Background
B-type natriuretic peptide (BNP) levels are reliably elevated in patients with congestive heart failure (CHF) and therefore helpful in its diagnosis. However, kidney disease results in elevated BNP levels independently of CHF. Accordingly, the impact of kidney disease on the benefit of BNP testing needs to be scrutinized.
Methods
This study evaluated patients with and without kidney disease [glomerular filtration rate (GFR) less than 60 mL/min/1.73m2) presenting with acute dyspnea. A total of 452 consecutive patients (240 with kidney disease and 212 without kidney disease) were randomly assigned to a diagnostic strategy with (BNP group) or without (control group) the use of BNP levels provided by a rapid bedside assay.
Results
Patients with kidney disease were older, more often had CHF as the cause of acute dyspnea, and more often died in-hospital or within 30 days as compared to patients without kidney disease. In patients without kidney disease, BNP testing significantly reduced median time to discharge (from 9.5 days to 2.5 days) (P = 0.003) and total cost of treatment (from $7184 to $4151) (P = 0.004). In contrast, in patients with kidney disease, time to discharge and total cost of treatment were similar in both groups.
Conclusion
When applying BNP cut-off values without adjustment for the presence of kidney disease, the use of BNP levels does significantly improve the management of patients without kidney disease, but not of those with kidney disease.
Keywords:
dyspnea, natriuretic peptides, emergency diagnosis, kidney disease
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated
REVIEWS
Cardiac biomarkers: a contemporary status report
Nature Clinical Practice Cardiovascular Medicine Review (01 Jan 2006)
Cardiac biomarkers: a contemporary status report
Nature Clinical Practice Cardiovascular Medicine Review (01 Jan 2006)
The prognostic value of N-terminal proB-type natriuretic peptide
Nature Clinical Practice Cardiovascular Medicine Review (01 Apr 2005)
NEWS AND VIEWS
Acute coronary syndromes BNP measurement predicts AMI risk in the elderly
Nature Reviews Cardiology News and Views (01 Aug 2009)
RESEARCH
Journal of Perinatology Original Article
